Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis after vitrectomy and subretinal alteplase for acute submacular hemorrhage in exudative age-related macular degeneration
2010-018637-21Phase 2Terminated
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Apr 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab and tissue-plasminogen activator in age-related macular degeneration (AMD), sponsored by Universitätsklinikum Schleswig-Holstein. Started Apr 2013; status: terminated.
02
Drugs
ranibizumabtissue-plasminogen activator
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2010-018637-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018637-21.